Psychopharmacology Practice Questions

Q: What is the treatment of choice for prophylaxis in patients with repeated episodes of bipolar illness?

Lithium and Valproate. **Explanation:** The management of Bipolar Affective Disorder (BPAD) often requires long-term prophylaxis to prevent relapses of both mania and depression. **Why Option C is Correct:** While Lithium and Valproate are both first-line agents individually, clinical evidence (notably the **BALANCE trial**) and various treatment guidelines (such as CANMAT) indicate that **combination therapy with Lithium and Valproate** is more effective than monotherapy for preventing relapse in patients with repeated episodes. This synergistic approach provides superior stabilization of mood, especially in patients who have failed monotherapy or those with high-frequency cycling. **Why Other Options are Incorrect:** * **Option A (Lithium):** Historically the "gold standard" for prophylaxis and excellent for preventing manic relapses and reducing suicide risk. However, as monotherapy, it may not be sufficient for patients with "repeated episodes" or rapid cycling compared to the combination. * **Option B (Valproate):** An effective first-line mood stabilizer, particularly for mixed episodes and rapid cycling. However, like Lithium, its efficacy in preventing all-cause relapse is statistically lower when used alone compared to the combination. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index. Prophylactic blood levels should be maintained between **0.6 – 0.8 mEq/L**. * **Drug of Choice (DOC):** * Acute Mania: Lithium (or Valproate). * Rapid Cycling BPAD: Valproate. * BPAD in Pregnancy: Second-generation antipsychotics (avoid Lithium/Valproate due to teratogenicity like Ebstein’s anomaly and Neural Tube Defects). * **Suicide Prevention:** Lithium is the only mood stabilizer proven to reduce the risk of completed suicide in BPAD patients.

Q: In which condition is the maximum benefit from Electroconvulsive Therapy (ECT) typically observed?

Depression with suicidal tendency. **Explanation:** The primary indication for **Electroconvulsive Therapy (ECT)** is Severe Depression, particularly when it is life-threatening or refractory to medications. **Why Option B is Correct:** ECT is considered the "gold standard" for rapid symptom relief in psychiatry. In **Depression with suicidal tendency**, the risk of self-harm is immediate. ECT works faster than antidepressants (which take 2–4 weeks to show effect), making it the treatment of choice to rapidly stabilize a patient and prevent suicide. Other high-priority indications include depressive stupor and psychotic depression. **Analysis of Incorrect Options:** * **A. Hysteria (Dissociative Disorders):** ECT has no therapeutic role here. Management involves psychotherapy and addressing underlying stressors. * **C. Chronic Schizophrenia:** While ECT is used in acute schizophrenia (especially catatonic or paranoid types), it is significantly less effective in chronic cases with negative symptoms or long-standing cognitive decline. * **D. Mania:** ECT is effective for acute mania (especially if delirious or treatment-resistant), but it is generally a second-line treatment after mood stabilizers and antipsychotics. **High-Yield Clinical Pearls for NEET-PG:** * **Most common indication:** Major Depressive Disorder (MDD). * **Most effective indication:** Catatonia (shows the fastest and most dramatic response). * **Absolute Contraindication:** Increased Intracranial Pressure (ICP) due to risk of brain herniation. * **Common Side Effect:** Retrograde amnesia (usually transient). * **Mechanism:** It is believed to work by increasing the seizure threshold and modulating neurotransmitter sensitivity (upregulation of serotonin and downregulation of β-receptors).

Q: A child with schizophrenia, who was on antipsychotic medications, suddenly developed neck stiffness and spasm. What is the best treatment for this condition?

Benzatropine. ### Explanation **Diagnosis: Acute Dystonia** The clinical presentation of sudden neck stiffness (torticollis) and muscle spasms in a patient taking antipsychotics is classic for **Acute Dystonia**. This is an Extrapyramidal Side Effect (EPS) caused by a sudden blockade of dopamine (D2) receptors in the nigrostriatal pathway, leading to a relative excess of cholinergic (acetylcholine) activity. **1. Why Benzatropine is the Correct Answer:** To restore the balance between dopamine and acetylcholine, a **centrally acting anticholinergic** drug is required. **Benzatropine** is the drug of choice (along with Trihexyphenidyl) because it effectively antagonizes muscarinic receptors in the basal ganglia, providing rapid relief from spasms. **2. Analysis of Incorrect Options:** * **Lorazepam (B):** A benzodiazepine used for Acute Akathisia (restlessness) or status epilepticus. While it has muscle-relaxant properties, it does not address the underlying cholinergic imbalance in dystonia. * **Diphenhydramine (C):** Although this antihistamine has significant anticholinergic properties and *can* be used to treat dystonia, **Benzatropine** is generally preferred in clinical guidelines and exam scenarios as the more specific first-line agent for drug-induced EPS. * **Propranolol (D):** This is a beta-blocker and is the **drug of choice for Akathisia**, not acute dystonia. **3. NEET-PG High-Yield Pearls:** * **Timeline of EPS:** Acute Dystonia (hours to days) → Akathisia (days to weeks) → Parkinsonism (weeks to months) → Tardive Dyskinesia (months to years). * **Acute Dystonia:** Most common in young males and those taking high-potency first-generation antipsychotics (e.g., Haloperidol). * **Tardive Dyskinesia:** The only EPS where anticholinergics are **contraindicated** (they worsen the condition). It is treated by switching to Clozapine or using VMAT-2 inhibitors (e.g., Valbenazine).

Q: A depressed patient does not want to take medication on a daily basis. Which selective serotonin reuptake inhibitor (SSRI) is most suitable for this patient?

Fluoxetine. **Explanation:** The correct answer is **Fluoxetine**. The primary pharmacological factor determining the suitability of an SSRI for a patient who struggles with daily adherence is the **elimination half-life**. 1. **Why Fluoxetine is correct:** Fluoxetine has the longest half-life of all SSRIs (approximately 2–4 days), and its active metabolite, **norfluoxetine**, has an even longer half-life of **7–15 days**. This long duration of action provides a "built-in" buffer; if a patient misses a dose, the plasma levels remain therapeutic for a longer period. It is also available as a once-weekly formulation in some regions, making it the drug of choice for patients with poor daily compliance. 2. **Why other options are incorrect:** * **Escitalopram:** Has a half-life of about 27–32 hours. It requires daily dosing to maintain steady-state levels. * **Fluvoxamine:** Has one of the shortest half-lives among SSRIs (approx. 15 hours) and often requires twice-daily dosing. * **Paroxetine:** Has a short half-life (approx. 21 hours) and no active metabolites. It is notorious for causing severe **discontinuation syndrome** if even a single dose is missed. **High-Yield Clinical Pearls for NEET-PG:** * **Discontinuation Syndrome:** Least common with Fluoxetine (due to long half-life) and most common with Paroxetine (due to short half-life and lack of metabolites). * **Drug Interactions:** Fluoxetine is a potent inhibitor of **CYP2D6**, which can lead to significant drug-drug interactions. * **Activating Effect:** Fluoxetine is the most "activating" SSRI; it is often taken in the morning to avoid insomnia. * **Weight Neutrality:** Fluoxetine is generally considered the most weight-neutral SSRI in the short term.

Q: Which of the following conditions is characterized by twisting and protrusion of the tongue, and chewing of the lips?

Tardive dyskinesia. **Explanation:** The clinical presentation of twisting and protrusion of the tongue (fly-catcher’s tongue) and repetitive chewing movements of the lips (bucco-linguo-masticatory movements) is a classic description of **Tardive Dyskinesia (TD)**. **1. Why Tardive Dyskinesia is correct:** TD is a delayed-onset extrapyramidal side effect (EPS) resulting from long-term blockade of dopamine (D2) receptors by antipsychotics. The underlying pathophysiology is **dopamine receptor supersensitivity** in the nigrostriatal pathway. It is characterized by involuntary, choreoathetoid movements, most commonly affecting the face, mouth, and tongue. **2. Why other options are incorrect:** * **Acute Akathisia:** Presents as subjective motor restlessness (e.g., inability to sit still, pacing). It does not involve involuntary orofacial movements. * **Acute Dystonia:** Characterized by sudden, sustained, and painful muscle contractions (e.g., torticollis, oculogyric crisis). It typically occurs within hours to days of starting medication, unlike the delayed onset of TD. * **Chronic Dystonia:** While persistent, dystonia involves sustained posturing rather than the rhythmic, repetitive "chewing" or "twisting" movements seen in dyskinesia. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Old age, female gender, and long-term use of typical antipsychotics (e.g., Haloperidol). * **Management:** The first step is to **taper/discontinue** the offending agent or switch to **Clozapine** (the antipsychotic with the lowest risk of TD). * **Specific Treatments:** VMAT-2 inhibitors like **Valbenazine** or **Deutetrabenazine** are FDA-approved for TD. * **Warning:** Anticholinergics (like Trihexyphenidyl) **worsen** Tardive Dyskinesia, whereas they help in Acute Dystonia.

Q: What is the treatment of acute manic episodes?

Sodium valproate. **Explanation:** The management of an **acute manic episode** focuses on rapid stabilization of mood and control of agitation. **Why Sodium Valproate is the correct answer:** Sodium Valproate is a first-line mood stabilizer for acute mania. It is often preferred over Lithium in clinical practice for acute episodes because it has a **faster onset of action** (usually within 3–5 days) and is highly effective for "mixed episodes" and "rapid cycling" bipolar disorder. In the context of this question, it represents the pharmacological gold standard for acute stabilization. **Analysis of Incorrect Options:** * **Lithium (Option B):** While Lithium is the "Gold Standard" for long-term maintenance and prophylaxis of Bipolar Disorder, it has a slower onset of action (5–7 days) compared to Valproate and a narrow therapeutic index, making it slightly less ideal for immediate acute control in some settings. * **Electroconvulsive Therapy (Option A):** ECT is highly effective for mania but is reserved as a **second-line** treatment. It is indicated only when pharmacological treatments fail, in cases of severe exhaustion, or during pregnancy. * **Diazepam (Option C):** Benzodiazepines like Diazepam or Lorazepam are used only as **adjuncts** to control agitation and sleep disturbance. They do not treat the underlying manic pathology. **High-Yield Clinical Pearls for NEET-PG:** * **First-line drugs for Acute Mania:** Lithium, Sodium Valproate, or Atypical Antipsychotics (e.g., Haloperidol, Risperidone, Olanzapine). * **Drug of Choice for Rapid Cyclers:** Sodium Valproate. * **Therapeutic Range for Lithium (Acute Mania):** 0.8 to 1.2 mEq/L. * **Teratogenicity:** Avoid Valproate in pregnancy (Neural Tube Defects); Lithium is associated with Ebstein’s Anomaly.

Q: A 4-year-old boy is brought to the physician by his parents for episodes of waking in the middle of the night screaming. The parents state that when they get to the boy's room during one of these episodes, they find him in his bed, thrashing wildly, with his eyes wide open. He pushes them away when they try to comfort him. After 2 minutes, the boy suddenly falls asleep and the next day has no memory of the episode. Which of the following medications is used to treat this disorder?

Diazepam. ### Explanation **Diagnosis: Sleep Terrors (Pavor Nocturnus)** The clinical presentation of a child with sudden nocturnal screaming, autonomic arousal (tachycardia/tachypnea), thrashing, and **complete amnesia** of the event the next morning is classic for **Sleep Terrors**. These occur during **Stage N3 (Slow-wave sleep)**, typically in the first third of the night. **Why Diazepam is Correct:** Sleep terrors occur during deep, slow-wave sleep (N3). **Benzodiazepines (like Diazepam)** are the treatment of choice for severe, persistent cases because they **suppress Stage N3 sleep**. By reducing the time spent in this deep sleep stage, the frequency and intensity of the episodes are diminished. Most cases are self-limiting and require only reassurance, but pharmacotherapy is indicated if the episodes are frequent or pose a risk of injury. **Analysis of Incorrect Options:** * **A. Haloperidol:** An antipsychotic used for schizophrenia or acute psychosis; it has no role in treating NREM parasomnias and may worsen sleep architecture. * **C. Methylphenidate:** A CNS stimulant used for ADHD and Narcolepsy. It would likely worsen sleep disturbances and cause insomnia. * **D. Amitriptyline:** A TCA sometimes used for enuresis or depression. While it affects REM sleep, it is not the first-line treatment for sleep terrors. **NEET-PG High-Yield Pearls:** * **Sleep Terrors vs. Nightmares:** * **Sleep Terrors:** Occur in **N3 (NREM)**; No memory of the dream; Difficult to arouse/comfort. * **Nightmares:** Occur in **REM sleep**; Vivid memory of the dream; Child is easily comforted. * **Age Group:** Most common in children aged 4–12 years. * **Management:** Reassurance is the first step. If medication is needed, low-dose Benzodiazepines (Diazepam/Clonazepam) are preferred.

Q: A 41-year-old man has been treated with haloperidol for his schizophrenia for the past 15 years. He begins to notice subtle involuntary movements of his hands, feet, lips, and tongue. Since he had been stable for over 1 year, his physician decided to decrease the dose. What would the physician tell the patient about the movement disorder?

It will increase initially as the medication is decreased.. **Explanation:** The patient is presenting with **Tardive Dyskinesia (TD)**, a late-onset extrapyramidal side effect caused by long-term use of first-generation antipsychotics like Haloperidol. **Why Option B is correct:** The underlying pathophysiology of TD involves **dopamine receptor supersensitivity**. Chronic blockade of $D_2$ receptors by haloperidol leads to an upregulation (increase in number and sensitivity) of these receptors in the nigrostriatal pathway. When the antipsychotic dose is decreased or discontinued, the "masking" effect of the drug is removed. This allows dopamine to act on these supersensitive receptors, which paradoxically **worsens or unmasks** the involuntary movements initially. This phenomenon is sometimes referred to as "withdrawal dyskinesia." **Why other options are incorrect:** * **Option A & D:** These are incorrect because decreasing the dose does not lead to immediate disappearance. In fact, symptoms often persist for months or may become permanent (irreversible) in many patients. * **Option C:** The movements rarely remain unchanged; they typically fluctuate in intensity following dosage adjustments due to the change in receptor occupancy. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Old age, female gender, and long-term use of typical antipsychotics. * **Clinical Feature:** Characterized by orofacial dyskinesia (tongue protrusion, lip-smacking, chewing) and choreoathetoid movements of limbs. * **Management:** 1. Prevention is key (use lowest effective dose). 2. Switch to **Clozapine** (the antipsychotic with the lowest risk of TD). 3. **VMAT-2 inhibitors** (e.g., Valbenazine, Deutetrabenazine) are now the first-line FDA-approved treatments for TD. * **Note:** Anticholinergics (like Trihexyphenidyl) **worsen** Tardive Dyskinesia, unlike other extrapyramidal symptoms.

Question 1

Propranolol, a non-selective beta-blocker, can be prescribed to decrease anxiety associated with which of the following conditions?

Accepted Answer

Short-term stressful situations

Answer

Chronic neurotic disorder

Answer

Schizophrenia

Answer

Endogenous depression

Question 2

What is the treatment of choice for prophylaxis in patients with repeated episodes of bipolar illness?

Accepted Answer

Lithium and Valproate

Answer

Lithium

Answer

Valproate

Answer

None of the above

Question 3

In which condition is the maximum benefit from Electroconvulsive Therapy (ECT) typically observed?

Accepted Answer

Depression with suicidal tendency

Answer

Hysteria

Answer

Chronic schizophrenia

Answer

Mania

Question 4

Which of the following SSRIs is used in the management of pathological emotions?

Accepted Answer

Escitalopram

Answer

Paroxetine

Answer

Clomipramine

Answer

Fluoxetine

Question 5

A child with schizophrenia, who was on antipsychotic medications, suddenly developed neck stiffness and spasm. What is the best treatment for this condition?

Accepted Answer

Benzatropine

Answer

Lorazepam

Answer

Diphenhydramine

Answer

Propranolol

Question 6

A depressed patient does not want to take medication on a daily basis. Which selective serotonin reuptake inhibitor (SSRI) is most suitable for this patient?

Accepted Answer

Fluoxetine

Answer

Escitalopram

Answer

Fluvoxamine

Answer

Paroxetine

Question 7

Which of the following conditions is characterized by twisting and protrusion of the tongue, and chewing of the lips?

Accepted Answer

Tardive dyskinesia

Answer

Acute Akathisia

Answer

Acute Dystonia

Answer

Chronic dystonia

Question 8

What is the treatment of acute manic episodes?

Accepted Answer

Sodium valproate

Answer

Electroconvulsive Therapy (ECT)

Answer

Lithium

Answer

Diazepam

Question 9

A 4-year-old boy is brought to the physician by his parents for episodes of waking in the middle of the night screaming. The parents state that when they get to the boy's room during one of these episodes, they find him in his bed, thrashing wildly, with his eyes wide open. He pushes them away when they try to comfort him. After 2 minutes, the boy suddenly falls asleep and the next day has no memory of the episode. Which of the following medications is used to treat this disorder?

Accepted Answer

Diazepam

Answer

Haloperidol

Answer

Methylphenidate

Answer

Amitriptyline

Question 10

A 41-year-old man has been treated with haloperidol for his schizophrenia for the past 15 years. He begins to notice subtle involuntary movements of his hands, feet, lips, and tongue. Since he had been stable for over 1 year, his physician decided to decrease the dose. What would the physician tell the patient about the movement disorder?

Accepted Answer

It will increase initially as the medication is decreased.

Answer

It will disappear as soon as the medication is decreased.

Answer

It will remain unchanged.

Answer

It will disappear in his hands but not his feet as soon as the medication is decreased.

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?